Literature DB >> 11038214

Method for dissection of mesenteric metastases in mid-gut carcinoid tumors.

U Ohrvall1, B Eriksson, C Juhlin, S Karacagil, J Rastad, P Hellman, G Akerström.   

Abstract

With adequate medical management the midgut carcinoid tumor generally is an indolent malignancy associated with substantial life expectancy and appreciable life quality, even in the presence of liver metastases and significant tumor burden. Abdominal complications may occur in this entity of carcinoids owing to entrapment of intestines and encasement of mesenteric vessels by mesenteric metastases and associated marked mesenteric fibrosis. This may be the cause of abdominal pain, disabling diarrhea, weight loss to the extent of malnutrition, and eventually the risk of death with acute or chronic intestinal obstruction or intestinal gangrene. Operative removal of the mesentericointestinal lesion is often indicated to prevent or treat these complications but may be technically difficult when mesenteric metastases extend in the vicinity of major vessels in the mesenteric root. At laparotomy 56 patients with advanced midgut carcinoids underwent removal of the mesenteric tumor with a method for preserving the mesenteric vessels. This was feasible by mobilizing and releasing the right colon and mesenteric root from posterior adhesions, identifying the mesenteric artery below the pancreas, and free-dissecting this artery on the tumor capsule in the mobilized mesentery. Dissection was successful even with tumors initially judged inoperable unless tumor growth completely surrounded the mesenteric vessels or extended retroperitoneally. One patient was subjected to distal intestinal artery bypass. Symptom relief was been substantial and often of long duration after mesenteric tumor removal in patients who prior to surgery often had threatening intestinal ischemia. Patients with advanced midgut carcinoids may benefit markedly from dissectional removal of mesenteric tumors, which (conceivably better than conventional wedge resection) preserves the length of the remaining intestine.

Entities:  

Mesh:

Year:  2000        PMID: 11038214     DOI: 10.1007/s002680010232

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  30 in total

Review 1.  Surgical treatment of gastrointestinal neuroendocrine tumors.

Authors:  Volker Fendrich; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2011-02-01       Impact factor: 3.445

2.  Partial abdominal evisceration and intestinal autotransplantation to resect a mesenteric carcinoid tumor.

Authors:  William H Kitchens; Nahel Elias; Lawrence S Blaszkowsky; A Benedict Cosimi; Martin Hertl
Journal:  World J Surg Oncol       Date:  2011-01-31       Impact factor: 2.754

Review 3.  Flushing Disorders Associated with Gastrointestinal Symptoms: Part 1, Neuroendocrine Tumors, Mast Cell Disorders and Hyperbasophila.

Authors:  Vaibhav Rastogi; Devina Singh; Joseph J Mazza; Dipendra Parajuli; Steven H Yale
Journal:  Clin Med Res       Date:  2018-04-12

Review 4.  [Extent of resection for neuroendocrine tumors of the small intestine].

Authors:  T J Musholt
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

Review 5.  Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.

Authors:  Romain Coriat; Thomas Walter; Benoît Terris; Anne Couvelard; Philippe Ruszniewski
Journal:  Oncologist       Date:  2016-07-08

Review 6.  Surgical Treatment of Small Intestinal Neuroendocrine Tumors G1/G2.

Authors:  Andreas Selberherr; Martin B Niederle; Bruno Niederle
Journal:  Visc Med       Date:  2017-10-06

Review 7.  Extent of Lymph Node Dissection for Small Bowel Neuroendocrine Tumors.

Authors:  Julie Hallet; Calvin Law
Journal:  World J Surg       Date:  2020-07-31       Impact factor: 3.352

8.  Ileal volvulus and its association with carcinoid tumours.

Authors:  Chee Leong
Journal:  Australas Med J       Date:  2012-06-30

Review 9.  Fibrosis and carcinoid syndrome: from causation to future therapy.

Authors:  Maralyn Druce; Andrea Rockall; Ashley B Grossman
Journal:  Nat Rev Endocrinol       Date:  2009-05       Impact factor: 43.330

Review 10.  Current management of gastrointestinal carcinoid tumors.

Authors:  Kenneth J Woodside; Courtney M Townsend; B Mark Evers
Journal:  J Gastrointest Surg       Date:  2004 Sep-Oct       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.